Last reviewed · How we verify
TG02 capsules oral administration, BIW in every 28d
TG02 capsules oral administration, BIW in every 28d is a Small molecule drug developed by Lee's Pharmaceutical Limited. It is currently in Phase 1 development.
At a glance
| Generic name | TG02 capsules oral administration, BIW in every 28d |
|---|---|
| Sponsor | Lee's Pharmaceutical Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TG02 capsules oral administration, BIW in every 28d CI brief — competitive landscape report
- TG02 capsules oral administration, BIW in every 28d updates RSS · CI watch RSS
- Lee's Pharmaceutical Limited portfolio CI
Frequently asked questions about TG02 capsules oral administration, BIW in every 28d
What is TG02 capsules oral administration, BIW in every 28d?
TG02 capsules oral administration, BIW in every 28d is a Small molecule drug developed by Lee's Pharmaceutical Limited.
Who makes TG02 capsules oral administration, BIW in every 28d?
TG02 capsules oral administration, BIW in every 28d is developed by Lee's Pharmaceutical Limited (see full Lee's Pharmaceutical Limited pipeline at /company/lee-s-pharmaceutical-limited).
What development phase is TG02 capsules oral administration, BIW in every 28d in?
TG02 capsules oral administration, BIW in every 28d is in Phase 1.